Will Mark Cuban’s PBM Deliver on Pricing Promises?

Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the drug pricing game. The PBMs promise low prices and transparency throughout their operations, ultimately leading to lower prescription drug costs for patients.

“Drug pricing is complicated and secretive. WSJ explains how the flow of money, drugs and rebates behind the scenes may drive up the price of prescription medicine for consumers.” Read more here.

(Source: Joseph Walker, The Wall Street Journal, 10/25/21)